IntroductionDespite drastic increases in antipsychotic prescribing in youth, data are still limited regarding their safety in this vulnerable population, necessitating additional tools for capturing long-term, real world data.
Methods:
We present SENTIA (SafEty of NeurolepTics in Infancy and Adolescence; https://SENTIA.es), an online registry created in 2010 to track antipsychotic adverse effects in Spanish youth
Additionally, efficacy and adverse effect data are recorded including the Children’s Global Assessment Scale; Clinical Global Impressions scale for Severity and Improvement, the Safety Monitoring Uniform Report Form, Simpson-Angus Scale, Abnormal Involuntary Movement Scale, vital signs, blood pressure, and EKG. Finally, fasting blood is drawn for hematology, electrolytes, renal, liver and thyroid function, glucose, insulin, lipid, prolactin and sex hormone levels.
Initially, a diagnostic interview and several psychopathology scales were also included. Patients are assessed regularly and followed even beyond stopping antipsychotics.
Results:
Since 01/17/2011, 85 youth (11.5 +/- 2.9 (range = 4-17) years old, 70.6% male) have been included at one inaugural center.
After a mean duration of 17 +/- 11 (range = 1-34) months, 78.8% are still actively followed. For feasibility reasons, the diagnostic interview and detailed psychopathology scales were dropped.
The remaining data can be entered in
Conclusions:
Implementation of a systematic online pharmacovigilance system for antipsychotic adverse effects in youth is feasible and promises to generate important information.
Author: Inmaculada Palanca-MarescaBelén Ruiz-AntoránGustavo Centeno-SotoSara Jiménez-FernandezLourdes GarcÃÂa-MurilloAna SilesSandra VillagráHilario Blasco-FontecillaLuis Iruela-CuadradoEnriqueta Roman-RiechmanCristina Avendaño-SoláChristoph U Corre
Published on: 2014-04-14
Tweet
News Provider: 7thSpace Interactive
Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo
There are no comments available. Be the first to write a comment.